Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Underutilization of Androgen Deprivation Therapy with External Beam Radiotherapy in Men with High-grade Prostate Cancer.

Wang C, Raldow AC, Nickols NG, Nguyen PL, Spratt DE, Dess RT, Yu JB, King CR, Chu FI, Chamie K, Litwin MS, Saigal CS, Reiter RE, Liu ST, Rettig MB, Chang AJ, Steinberg ML, Kupelian PA, Kishan AU.

Eur Urol Oncol. 2019 Feb 1. pii: S2588-9311(19)30007-0. doi: 10.1016/j.euo.2019.01.006. [Epub ahead of print]

PMID:
31411981
2.

Multi-institutional Analysis of Prostate-Specific Antigen Kinetics Following Stereotactic Body Radiotherapy (SBRT).

Jiang NY, Dang AT, Yuan Y, Chu FI, Shabsovich D, King CR, Collins SP, Aghdam N, Suy S, Mantz CA, Miszczyk L, Napieralska A, Namysl-Kaletka A, Bagshaw H, Prionas N, Buyyounouski MK, Jackson WC, Spratt DE, Nickols NG, Steinberg ML, Kupelian PA, Kishan AU.

Int J Radiat Oncol Biol Phys. 2019 Jul 2. pii: S0360-3016(19)33427-3. doi: 10.1016/j.ijrobp.2019.06.2539. [Epub ahead of print]

PMID:
31276777
3.

Testosterone Levels and Sexual Quality of Life After Stereotactic Body Radiation Therapy for Prostate Cancer: A Multi-Institutional Analysis of Prospective Trials.

Yuan Y, Aghdam N, King CR, Fuller DB, Weng J, Chu FI, Mardirossian G, Patel A, Nickols NG, Kupelian PA, Steinberg ML, Collins SP, Kishan AU.

Int J Radiat Oncol Biol Phys. 2019 Sep 1;105(1):149-154. doi: 10.1016/j.ijrobp.2019.05.014. Epub 2019 May 17.

PMID:
31108142
4.

Prostate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis.

Sandler KA, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Stock RG, Merrick GS, Demanes DJ, Spratt DE, Abu-Isa EI, Wedde TB, Lilleby W, Krauss DJ, Shaw GK, Alam R, Reddy CA, Song DY, Klein EA, Stephenson AJ, Tosoian JJ, Hegde JV, Yoo SM, Fiano R, D'Amico AV, Nickols NG, Aronson WJ, Sadeghi A, Greco SC, Deville C Jr, McNutt T, DeWeese TL, Reiter RE, Said JW, Steinberg ML, Horwitz EM, Kupelian PA, King CR, Kishan AU.

Eur Urol. 2019 Apr 13. pii: S0302-2838(19)30208-8. doi: 10.1016/j.eururo.2019.03.022. [Epub ahead of print]

PMID:
30992160
5.

Systemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic disease.

Parikh NR, Huiza C, Patel JS, Tsai S, Kalpage N, Thein M, Pitcher S, Lee SP, Inouye WS, Jordan ML, Sanati H, Jafari L, Bennett CJ, Gin GE, Kishan AU, Reiter RE, Lewis M, Sadeghi A, Aronson WJ, Garraway IP, Rettig MB, Nickols NG.

BMC Cancer. 2019 Apr 1;19(1):291. doi: 10.1186/s12885-019-5496-5.

6.

MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer.

Nickols NG, Nazarian R, Zhao SG, Tan V, Uzunangelov V, Xia Z, Baertsch R, Neeman E, Gao AC, Thomas GV, Howard L, De Hoedt AM, Stuart J, Goldstein T, Chi K, Gleave ME, Graff JN, Beer TM, Drake JM, Evans CP, Aggarwal R, Foye A, Feng FY, Small EJ, Aronson WJ, Freedland SJ, Witte ON, Huang J, Alumkal JJ, Reiter RE, Rettig MB.

Prostate Cancer Prostatic Dis. 2019 Feb 25. doi: 10.1038/s41391-019-0134-5. [Epub ahead of print]

PMID:
30804427
7.

Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer.

Kishan AU, Dang A, Katz AJ, Mantz CA, Collins SP, Aghdam N, Chu FI, Kaplan ID, Appelbaum L, Fuller DB, Meier RM, Loblaw DA, Cheung P, Pham HT, Shaverdian N, Jiang N, Yuan Y, Bagshaw H, Prionas N, Buyyounouski MK, Spratt DE, Linson PW, Hong RL, Nickols NG, Steinberg ML, Kupelian PA, King CR.

JAMA Netw Open. 2019 Feb 1;2(2):e188006. doi: 10.1001/jamanetworkopen.2018.8006.

8.

Correction to: Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT].

Calais J, Czernin J, Fendler WP, Elashoff D, Nickols NG.

BMC Cancer. 2019 Jan 21;19(1):97. doi: 10.1186/s12885-019-5297-x.

9.

Spatial Mapping of Myeloid Cells and Macrophages by Multiplexed Tissue Staining.

Saylor J, Ma Z, Goodridge HS, Huang F, Cress AE, Pandol SJ, Shiao SL, Vidal AC, Wu L, Nickols NG, Gertych A, Knudsen BS.

Front Immunol. 2018 Dec 14;9:2925. doi: 10.3389/fimmu.2018.02925. eCollection 2018.

10.

Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT].

Calais J, Czernin J, Fendler WP, Elashoff D, Nickols NG.

BMC Cancer. 2019 Jan 7;19(1):18. doi: 10.1186/s12885-018-5200-1. Erratum in: BMC Cancer. 2019 Jan 21;19(1):97.

11.

Treatment of the primary tumor in metastatic prostate cancer.

Yuan Y, Kishan AU, Nickols NG.

World J Urol. 2018 Nov 19. doi: 10.1007/s00345-018-2552-8. [Epub ahead of print]

PMID:
30456709
12.

Association of Gleason Grade With Androgen Deprivation Therapy Duration and Survival Outcomes: A Systematic Review and Patient-Level Meta-analysis.

Kishan AU, Wang X, Seiferheld W, Collette L, Sandler KA, Sandler HM, Bolla M, Maingon P, De Reijke T, Hanks GE, Nickols NG, Rettig M, Drakaki A, Reiter RE, Spratt DE, Kupelian PA, Steinberg ML, King CR.

JAMA Oncol. 2019 Jan 1;5(1):91-96. doi: 10.1001/jamaoncol.2018.3732.

PMID:
30326032
13.

Clinical Outcomes for Patients With Gleason Score 10 Prostate Adenocarcinoma: Results From a Multi-institutional Consortium Study.

Sandler KA, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Stock RG, Merrick GS, Demanes DJ, Spratt DE, Abu-Isa EI, Wedde TB, Lilleby W, Krauss DJ, Shaw GK, Alam R, Reddy CA, Song DY, Klein EA, Stephenson AJ, Tosoian JJ, Hegde JV, Yoo SM, Fiano R, D'Amico AV, Nickols NG, Aronson WJ, Sadeghi A, Greco SC, Deville C, McNutt T, DeWeese TL, Reiter RE, Said JW, Steinberg ML, Horwitz EM, Kupelian PA, King CR, Kishan AU.

Int J Radiat Oncol Biol Phys. 2018 Jul 15;101(4):883-888. doi: 10.1016/j.ijrobp.2018.03.060. Epub 2018 Apr 5.

PMID:
29976500
14.

Interference with DNA repair after ionizing radiation by a pyrrole-imidazole polyamide.

Diaz-Perez S, Kane N, Kurmis AA, Yang F, Kummer NT, Dervan PB, Nickols NG.

PLoS One. 2018 May 1;13(5):e0196803. doi: 10.1371/journal.pone.0196803. eCollection 2018.

15.

Potential Impact of 68Ga-PSMA-11 PET/CT on the Planning of Definitive Radiation Therapy for Prostate Cancer.

Calais J, Kishan AU, Cao M, Fendler WP, Eiber M, Herrmann K, Ceci F, Reiter RE, Rettig MB, Hegde JV, Shaverdian N, King CR, Steinberg ML, Czernin J, Nickols NG.

J Nucl Med. 2018 Nov;59(11):1714-1721. doi: 10.2967/jnumed.118.209387. Epub 2018 Apr 13.

16.

Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer.

Kishan AU, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Sandler KA, Stock RG, Merrick GS, Demanes DJ, Spratt DE, Abu-Isa EI, Wedde TB, Lilleby W, Krauss DJ, Shaw GK, Alam R, Reddy CA, Stephenson AJ, Klein EA, Song DY, Tosoian JJ, Hegde JV, Yoo SM, Fiano R, D'Amico AV, Nickols NG, Aronson WJ, Sadeghi A, Greco S, Deville C, McNutt T, DeWeese TL, Reiter RE, Said JW, Steinberg ML, Horwitz EM, Kupelian PA, King CR.

JAMA. 2018 Mar 6;319(9):896-905. doi: 10.1001/jama.2018.0587.

17.

The Utility of PET/CT in the Planning of External Radiation Therapy for Prostate Cancer.

Calais J, Cao M, Nickols NG.

J Nucl Med. 2018 Apr;59(4):557-567. doi: 10.2967/jnumed.117.196444. Epub 2018 Jan 4.

18.

Impact of 68Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence.

Calais J, Fendler WP, Eiber M, Gartmann J, Chu FI, Nickols NG, Reiter RE, Rettig MB, Marks LS, Ahlering TE, Huynh LM, Slavik R, Gupta P, Quon A, Allen-Auerbach MS, Czernin J, Herrmann K.

J Nucl Med. 2018 Mar;59(3):434-441. doi: 10.2967/jnumed.117.202945. Epub 2017 Dec 14.

19.

68Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning.

Calais J, Czernin J, Cao M, Kishan AU, Hegde JV, Shaverdian N, Sandler K, Chu FI, King CR, Steinberg ML, Rauscher I, Schmidt-Hegemann NS, Poeppel T, Hetkamp P, Ceci F, Herrmann K, Fendler WP, Eiber M, Nickols NG.

J Nucl Med. 2018 Feb;59(2):230-237. doi: 10.2967/jnumed.117.201749. Epub 2017 Nov 9.

20.

Pretreatment 3T multiparametric MRI staging predicts for biochemical failure in high-risk prostate cancer treated with combination high-dose-rate brachytherapy and external beam radiotherapy.

Hegde JV, Demanes DJ, Veruttipong D, Raince J, Park SJ, Raman SS, Nickols NG, King CR, Kishan AU, Steinberg ML, Kamrava M.

Brachytherapy. 2017 Nov - Dec;16(6):1106-1112. doi: 10.1016/j.brachy.2017.07.008. Epub 2017 Aug 12.

PMID:
28807747
21.

A Pyrrole-Imidazole Polyamide Is Active against Enzalutamide-Resistant Prostate Cancer.

Kurmis AA, Yang F, Welch TR, Nickols NG, Dervan PB.

Cancer Res. 2017 May 1;77(9):2207-2212. doi: 10.1158/0008-5472.CAN-16-2503. Epub 2017 Mar 30.

22.

Clinical Outcomes for Patients with Gleason Score 9-10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis.

Kishan AU, Shaikh T, Wang PC, Reiter RE, Said J, Raghavan G, Nickols NG, Aronson WJ, Sadeghi A, Kamrava M, Demanes DJ, Steinberg ML, Horwitz EM, Kupelian PA, King CR.

Eur Urol. 2017 May;71(5):766-773. doi: 10.1016/j.eururo.2016.06.046. Epub 2016 Jul 21.

PMID:
27452951
23.

SBRT and HDR brachytherapy produce lower PSA nadirs and different PSA decay patterns than conventionally fractionated IMRT in patients with low- or intermediate-risk prostate cancer.

Kishan AU, Wang PC, Upadhyaya SK, Hauswald H, Demanes DJ, Nickols NG, Kamrava M, Sadeghi A, Kupelian PA, Steinberg ML, Prionas ND, Buyyounouski MK, King CR.

Pract Radiat Oncol. 2016 Jul-Aug;6(4):268-75. doi: 10.1016/j.prro.2015.11.002. Epub 2015 Nov 10.

PMID:
26850649
24.

Animal toxicity of hairpin pyrrole-imidazole polyamides varies with the turn unit.

Yang F, Nickols NG, Li BC, Szablowski JO, Hamilton SR, Meier JL, Wang CM, Dervan PB.

J Med Chem. 2013 Sep 26;56(18):7449-57. doi: 10.1021/jm401100s. Epub 2013 Sep 9.

25.

Activity of a Py-Im polyamide targeted to the estrogen response element.

Nickols NG, Szablowski JO, Hargrove AE, Li BC, Raskatov JA, Dervan PB.

Mol Cancer Ther. 2013 May;12(5):675-84. doi: 10.1158/1535-7163.MCT-12-1040. Epub 2013 Feb 26.

26.

Antitumor activity of a pyrrole-imidazole polyamide.

Yang F, Nickols NG, Li BC, Marinov GK, Said JW, Dervan PB.

Proc Natl Acad Sci U S A. 2013 Jan 29;110(5):1863-8. doi: 10.1073/pnas.1222035110. Epub 2013 Jan 14.

27.

Gene expression changes in a tumor xenograft by a pyrrole-imidazole polyamide.

Raskatov JA, Nickols NG, Hargrove AE, Marinov GK, Wold B, Dervan PB.

Proc Natl Acad Sci U S A. 2012 Oct 2;109(40):16041-5. doi: 10.1073/pnas.1214267109. Epub 2012 Sep 17.

28.

Single-dose pharmacokinetic and toxicity analysis of pyrrole-imidazole polyamides in mice.

Synold TW, Xi B, Wu J, Yen Y, Li BC, Yang F, Phillips JW, Nickols NG, Dervan PB.

Cancer Chemother Pharmacol. 2012 Oct;70(4):617-25. Epub 2012 Aug 21.

29.

Repression of DNA-binding dependent glucocorticoid receptor-mediated gene expression.

Muzikar KA, Nickols NG, Dervan PB.

Proc Natl Acad Sci U S A. 2009 Sep 29;106(39):16598-603. doi: 10.1073/pnas.0909192106. Epub 2009 Sep 15.

30.

Modulating hypoxia-inducible transcription by disrupting the HIF-1-DNA interface.

Nickols NG, Jacobs CS, Farkas ME, Dervan PB.

ACS Chem Biol. 2007 Aug 17;2(8):561-71.

31.

Suppression of androgen receptor-mediated gene expression by a sequence-specific DNA-binding polyamide.

Nickols NG, Dervan PB.

Proc Natl Acad Sci U S A. 2007 Jun 19;104(25):10418-23. Epub 2007 Jun 12.

32.

Improved nuclear localization of DNA-binding polyamides.

Nickols NG, Jacobs CS, Farkas ME, Dervan PB.

Nucleic Acids Res. 2007;35(2):363-70. Epub 2006 Dec 14.

33.

Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist.

Olenyuk BZ, Zhang GJ, Klco JM, Nickols NG, Kaelin WG Jr, Dervan PB.

Proc Natl Acad Sci U S A. 2004 Nov 30;101(48):16768-73. Epub 2004 Nov 19.

34.

Influence of structural variation on nuclear localization of DNA-binding polyamide-fluorophore conjugates.

Edelson BS, Best TP, Olenyuk B, Nickols NG, Doss RM, Foister S, Heckel A, Dervan PB.

Nucleic Acids Res. 2004 May 20;32(9):2802-18. Print 2004.

35.

Nuclear localization of pyrrole-imidazole polyamide-fluorescein conjugates in cell culture.

Best TP, Edelson BS, Nickols NG, Dervan PB.

Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12063-8. Epub 2003 Sep 30.

Supplemental Content

Loading ...
Support Center